CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to CLSD

triamcinolone acetonide (Triesence®)

Phase 2
Clearside Biomedical, Inc. (CLSD)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

4 competitors in Uveitis

View Full Landscape
Drug Information

Target Indication

Uveitis

Clinical Trial

NCT01789320

Last updated: 12/4/2025

Patent & Exclusivity
ActiveRLD

Latest Patent Expiry

Apr 16, 2040(13y 8m)

Patents Listed

8

Application

NDA 211950
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.